Rome

• Clinical trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycyclin … Ended
  2024-513426-29-00 4 2013-03-19 Patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (O
• Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended
  2023-506419-16-00 5 2013-01-08 Advanced Classical Hodgkin Lymphoma
• A safety and efficacy extension of study HGT-MLD-070 in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement b … Ended
  2024-514403-34-00 9 2012-10-10 Late Metachromatic Leukodystrophy (MLD)
• EQU-001 as an Add-On Drug for People with Focal Seizures while on Medication Ended
  2022-500302-18-00 4 Epilepsy
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended
  2022-500691-59-00 4 Alzheimer's disease (AD)
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5 Reversal of anticoagulation effect in patients on a FXa inhibitor (api
• A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended
  2022-501474-19-00 7 Non-Small Cell Lung Cancer
• Phase 1/2 Study of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD) Ended
  2022-502096-32-00 7 Facioscapulohumeral muscular dystrophy (FSHD)
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 6) Ended
  2022-502268-18-00 5 Neurocognitive Disorders
• A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC Ended
  2022-503007-22-00 4 Non-small Cell Lung Cancer
• A Phase 1/2 Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors Ended
  2022-503060-33-00 4 Advanced or Metastatic Solid Tumor Malignancies
• Study of Obeldesivir in Children and Adolescents With COVID-19 Ended
  2023-503282-27-00 10 COVID-19
• A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmaco … Ended
  2023-503926-37-00 10 Biliary Atresia, Post-hepatoportoenterostomy
• Brightline-4: A study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma Ended
  2023-504522-19-00 5 dedifferentiated liposarcoma
• Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended
  2023-504963-17-00 9 Advanced ccRCC
• Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended
  2023-505070-15-00 9 Oncology, NSCLC and CRC
• A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with … Ended
  2023-506240-16-00 9 Acute Myeloid Leukemia (AML)
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edem … Ended
  2023-507207-66-00 5 Diabetic Macular Edema (DME)
• A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload … Ended
  2023-508604-37-00 4 Non-transfusion dependent beta-thalassemia (NTDT), Beta-thalassemia Re
• Study of SKB264 in patients with advanced and hard-to-treat cancers who have not responded well to standard treatments. Ended
  2023-508700-38-00 4 Metastatic or locally advanced unresectable solid tumors progressing a
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in post-COVID-19 POTS Ended
  2023-508744-22-00 5 Post-COVID-19 Postural Orthostatic Tachycardia Syndrome
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall … Ended
  2024-512477-27-00 4 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar

Showing 2,113–2,136 of 2,140 trials